Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04263090
Title Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Icahn School of Medicine at Mount Sinai
Indications

lung adenocarcinoma

Therapies

Nivolumab + Rigosertib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST